Leonteq Securities’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$888K Buy
27,232
+11,775
+76% +$408K 0.04% 251
2026
Q2
$603K Sell
15,457
-7,355
-32% -$238K 0.02% 363
2026
Q1
$742K Buy
22,812
+8,951
+65% +$288K 0.03% 339
2025
Q4
$488K Sell
13,861
-294
-2% -$10.4K 0.01% 469
2025
Q3
$372K Buy
14,155
+4,549
+47% +$136K 0.01% 468
2025
Q2
$255K Sell
9,606
-6,041
-39% -$159K 0.01% 514
2025
Q1
$375K Buy
15,647
+4,279
+38% +$135K 0.02% 414
2024
Q4
$457K Buy
11,368
+3,309
+41% +$189K 0.03% 376
2024
Q3
$510K Buy
8,059
+3,655
+83% +$214K 0.04% 321
2024
Q2
$233K Buy
4,404
+1,346
+44% +$88.2K 0.02% 449
2024
Q1
$251K Buy
3,058
+2,958
+2,958% +$132K 0.02% 457
2023
Q4
$1.86K Buy
+100
New +$1.31K ﹤0.01% 1124

Other funds holding VKTX

Leonteq Securities's VKTX Position: Q3 2026 in Review

Leonteq Securities increased its Viking Therapeutics (VKTX) stake by 76% in Q3 2026, buying an estimated $408K and bringing the position to 27,232 shares worth $888K. The position accounts for 0.04% of the portfolio, ranked #251.

Leonteq Securities first reported a position in VKTX in Q4 2023 and has held it in 12 quarters since. 444 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Leonteq Securities held 27,232 shares of Viking Therapeutics worth $888K as of Q3 2026.
  • Leonteq Securities bought 11,775 Viking Therapeutics shares in Q3 2026, an estimated $408K.
  • Viking Therapeutics made up 0.04% of Leonteq Securities's portfolio in Q3 2026, its #251 holding.
  • Leonteq Securities first reported a position in Viking Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • 444 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.